AGMB
Agomab Therapeutics NVBS score 38.0LOWPHASE2 · mkt cap $502.5M · rev ttm $0
drug hypothesis
AGMB-129 modulates Not provided in the clinical trial data - this is a Phase 1 drug-drug interaction study, not an efficacy trial to treat Not applicable - this study enrolled healthy volunteers (n=14) to assess drug-drug interaction pharmacokinetics, not patients with a disease.
moa:Not provided in the clinical trial data
score breakdown
trial design55
base rate disconnect20
language red flags40
composite38.0
valuation analysis
market cap$502.5M
revenue ttm$0
phasePHASE2
historical base rate15%
disconnect ratio0.7x
lead trialNCT05937386
meta
cik0002020932
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 1, non-randomized, single-arm, open-label drug-drug interaction study evaluating the effect of AGMB-129 on midazolam pharmacokinetics in 14 healthy adult participants. Study conducted August-September 2023.
primary endpoint:Cmax (maximum concentration) for midazolam (MDZ) from Day 1 to Day 13
claimed differentiation
Not provided in the clinical trial data
language red flags
- The provided data is a routine Phase 1 pharmacokinetic study in healthy volunteers, not a pivotal efficacy trial or SEC filing with claims about drug differentiation, target, or mechanism of action
- No marketing language or claims about 'best-in-class', 'revolutionary', or 'proprietary'platforms are present in this clinical trial dataset
company-stated risks
- Not explicitly stated in the clinical trial data - routine Phase 1 safety monitoring through adverse event collection, clinical laboratory values, vital signs, and physical examinations were listed as secondary endpoints